We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Melanoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
N. Engl. J. Med 2023 Mar 02;388(9)813-823, SP Patel, M Othus, Y Chen, GP Wright, KJ Yost, JR Hyngstrom, S Hu-Lieskovan, CD Lao, LA Fecher, TG Truong, JL Eisenstein, S Chandra, JA Sosman, KL Kendra, RC Wu, CE Devoe, GB Deutsch, A Hegde, M Khalil, A Mangla, AM Reese, MI Ross, AS Poklepovic, GQ Phan, AA Onitilo, DG Yasar, BC Powers, GC Doolittle, GK In, N Kokot, GT Gibney, MB Atkins, M Shaheen, JA Warneke, A Ikeguchi, JE Najera, B Chmielowski, JG Crompton, JD Floyd, E Hsueh, KA Margolin, WA Chow, KF Grossmann, E Dietrich, VG Prieto, MC Lowe, EI Buchbinder, JM Kirkwood, L Korde, J Moon, E Sharon, VK Sondak, A Ribas